Laboratory of Lymphocyte Signaling and Oncoproteome

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL

Missense mutations of JAK and STAT genes are frequently found in T-PLL. However, sequencing analyses of the JAK/STAT pathway have been performed in small cohorts, due to the limited number of patient samples. Here we conducted a meta-analysis that re-evaluated the genomic landscape of the JAK/STAT pathway and its regulators in 275 T-PLL cases. Interestingly, next to gain of function mutations in JAK and STAT genes, a significant proportion of genes encoding for potential negative regulators of STAT5B showed genomic losses. Overall, considering such losses of negative regulators and the GOF mutations in JAK and STAT genes, we found that a total of 89.8% of T-PLL revealed a genomic aberration potentially explaining enhanced STAT5B activity.

Read the paper:

JAK/STAT-Activating Genomic Alterations Are a Hallmark of T-PLL

Postet on November 21, 2019

More news

New article accepted for publication

New article accepted for publication

August 30, 2020

Our work on T-PLL cells resembling the phenotype of activated memory-type effector T-cells has been accepted in Blood

Alkylating deacetylase inhibitor tinostamustine in T-PLL

March 11, 2020

New letter evaluating the effects of EDO-S101/tinostamustine published in Leukemia.